• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    NewAmsterdam Pharma Company N.V. - Ordinary Shares (NQ:NAMS)

    32.48 +0.11 (+0.32%)
    Streaming Delayed Price Updated: 12:41 PM EST, Jan 27, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 120,020
    Open 32.66
    Bid (Size) 32.46 (100)
    Ask (Size) 32.57 (100)
    Prev. Close 32.37
    Today's Range 32.29 - 33.00
    52wk Range 14.06 - 42.00
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire

    Performance

    YTD
    -7.7%
    -7.7%
    1 Month
    -7.3%
    -7.3%
    3 Month
    -9.9%
    -9.9%
    6 Month
    +38.7%
    +38.7%
    1 Year
    +43.6%
    +43.6%

    More News

    Read More
    News headline image
    NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    Investment Powerhouse Backs Biotech Stock to the Tune of $419 Million ↗
    Via The Motley Fool
    Topics Artificial Intelligence Regulatory Compliance
    News headline image
    Institutional Titan Hits the Jackpot: Biotech Stock Surges by 116% on Buyout Offer ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Biotech Stock Gets Booted in Latest Fund Update ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Portfolio Adjustment: Institutional Heavyweight Exits Biotech Stock ↗
    Via The Motley Fool
    News headline image
    Why Bain Capital Is Selling Shares of This Biotech Stock Now ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in November
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    Deep Dive Into NewAmsterdam Pharma Co Stock: Analyst Perspectives (4 Ratings) ↗
    Via Benzinga
    News headline image
    NewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    Expert Outlook: NewAmsterdam Pharma Co Through The Eyes Of 6 Analysts ↗
    Via Benzinga
    News headline image
    NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in September
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    What 5 Analyst Ratings Have To Say About NewAmsterdam Pharma Co ↗
    Via Benzinga
    News headline image
    NewAmsterdam (NAMS) Q2 Revenue Jumps 49% ↗
    Via The Motley Fool
    News headline image
    NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer’s Disease Biomarkers at AAIC 2025
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    NewAmsterdam Pharma to Present Alzheimer’s Biomarker Data from BROADWAY Trial at AAIC 2025
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    What Analysts Are Saying About NewAmsterdam Pharma Co Stock ↗
    Via Benzinga
    News headline image
    Analyst Says NewAmsterdam Stock Has Over 100% Upside, Citing 90% Success Probability For Obicetrapib ↗
    Via Benzinga
    News headline image
    Get insights into the top gainers and losers of Monday's pre-market session. ↗
    Via Chartmill

    Frequently Asked Questions

    Is NewAmsterdam Pharma Company N.V. - Ordinary Shares publicly traded?
    Yes, NewAmsterdam Pharma Company N.V. - Ordinary Shares is publicly traded.
    What exchange does NewAmsterdam Pharma Company N.V. - Ordinary Shares trade on?
    NewAmsterdam Pharma Company N.V. - Ordinary Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for NewAmsterdam Pharma Company N.V. - Ordinary Shares?
    The ticker symbol for NewAmsterdam Pharma Company N.V. - Ordinary Shares is NAMS on the Nasdaq Stock Market
    What is the current price of NewAmsterdam Pharma Company N.V. - Ordinary Shares?
    The current price of NewAmsterdam Pharma Company N.V. - Ordinary Shares is 32.48
    When was NewAmsterdam Pharma Company N.V. - Ordinary Shares last traded?
    The last trade of NewAmsterdam Pharma Company N.V. - Ordinary Shares was at 01/27/26 12:41 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.